Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04753515
Other study ID # E2020154
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date March 5, 2021
Est. completion date May 1, 2021

Study information

Verified date November 2022
Source Sixth Affiliated Hospital, Sun Yat-sen University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare the sedation effect of dexmedetomidine and propofol when they are both combined with midazolam and remifentanil during awake endotracheal intubation.


Description:

Awake intubation is one of the best strategy guaranteed by the American Society of Anesthesiologists (ASA) guidelines for the management of patients with anticipated difficult airways. Hemodynamic stability, optimal intubating conditions, patients' comfort, amnesia and preservation of patents' spontaneous respiration are critical for awake intubation. Sedation is one of the key elements for this technique. Intravenous midazolam, propofol, dexmedetomidine and remifentanil are commonly used as sedatives during awake intubation. These agents are not preferred to be used alone but in combination with each other for the purpose of minimizing their respective side effects. The aim of this randomized controlled trial is to compare the safety and effectiveness of dexmedetomidine versus propofol for sedation during awake endotracheal intubation when they are both combined with midazolam and remifentanil.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date May 1, 2021
Est. primary completion date May 1, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Age 18-65 Years old; 2. scheduled for elective surgery under general anesthesia with oral tracheal intubation; 3. The American Society of Anesthesiologists(ASA) grade is I or II, and the cardiac function is 1-2; 4. Body mass index (BMI) 18-30 kg/m2. Exclusion Criteria: 1. Patients have severe cardiac diseases (cardiac function grading greater than grade 3/arrhythmia including sick sinus syndrome, atrial fibrillation, atrial flutter, atrioventricular block, frequent ventricular premature, multiple ventricular premature, ventricular premature R on T, ventricular fibrillation and ventricular flutter/acute coronary syndrome) or respiratory failure or hepatic failure or renal failure; 2. body mass index (BMI) =30 kg/m2 or <18 kg/m2; 3. Patients with poor blood pressure control (receive regular antihypertensive medical treatment but still have systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 90 mmHg); 4. Patients with a higher risk of reflux and aspiration, such as full stomach, gastrointestinal obstruction, gastroparesis, and pregnant women; 5. Patients have schizophrenia, epilepsy, Parkinson's disease, intellectual disability, hearing impairment.; 6. Patients who take sedative and analgesic drugs for a long time; 7. Patients who are allergic to propofol, dexmedetomidine, midazolam or remifentanil 8. Patients who are expected to be difficult to intubate; 9. Patients who are participating in other clinical trials, or who refuse to sign informed consent.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
dexmedetomidine combined with midazolam and remifentanil.
Patients in this group will receive a bolus of midazolam 0.03 mg/kg intravenously, and then a loading dose of 0.5 mcg/kg remifentanil and 0.5 mcg/kg dexmedetomidine over 5 min via separate syringe pumps.
propofol combined with midazolam and remifentanil.
Patients in this group will receive a bolus of midazolam 0.03 mg/kg intravenously, and then a loading dose of 0.5 mcg/kg remifentanil and 0.33 mg/kg propoful over 5 min via separate syringe pumps.

Locations

Country Name City State
China the Sixth Affiliated Hospital, Sun Yat-sen University Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Sixth Affiliated Hospital, Sun Yat-sen University

Country where clinical trial is conducted

China, 

References & Publications (6)

Apfelbaum JL, Hagberg CA, Caplan RA, Blitt CD, Connis RT, Nickinovich DG, Hagberg CA, Caplan RA, Benumof JL, Berry FA, Blitt CD, Bode RH, Cheney FW, Connis RT, Guidry OF, Nickinovich DG, Ovassapian A; American Society of Anesthesiologists Task Force on Management of the Difficult Airway. Practice guidelines for management of the difficult airway: an updated report by the American Society of Anesthesiologists Task Force on Management of the Difficult Airway. Anesthesiology. 2013 Feb;118(2):251-70. doi: 10.1097/ALN.0b013e31827773b2. No abstract available. — View Citation

Cattano D, Lam NC, Ferrario L, Seitan C, Vahdat K, Wilcox DW, Hagberg CA. Dexmedetomidine versus Remifentanil for Sedation during Awake Fiberoptic Intubation. Anesthesiol Res Pract. 2012;2012:753107. doi: 10.1155/2012/753107. Epub 2012 Jul 16. — View Citation

Johnston KD, Rai MR. Conscious sedation for awake fibreoptic intubation: a review of the literature. Can J Anaesth. 2013 Jun;60(6):584-99. doi: 10.1007/s12630-013-9915-9. Epub 2013 Mar 20. Review. — View Citation

Park S, Choi SL, Nahm FS, Ryu JH, Do SH. Dexmedetomidine-remifentanil vs propofol-remifentanil for monitored anesthesia care during hysteroscopy: Randomized, single-blind, controlled trial. Medicine (Baltimore). 2020 Oct 23;99(43):e22712. doi: 10.1097/MD.0000000000022712. — View Citation

Xu T, Li M, Ni C, Guo XY. Dexmedetomidine versus remifentanil for sedation during awake intubation using a Shikani optical stylet: a randomized, double-blinded, controlled trial. BMC Anesthesiol. 2016 Aug 2;16(1):52. doi: 10.1186/s12871-016-0219-9. — View Citation

Zhou LJ, Fang XZ, Gao J, Zhangm Y, Tao LJ. Safety and Efficacy of Dexmedetomidine as a Sedative Agent for Performing Awake Intubation: A Meta-analysis. Am J Ther. 2016 Nov/Dec;23(6):e1788-e1800. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other degree of coughing Grade assessment of coughing during the peri-intubation period (1 = No cough and limb activity, 2 = Intermittent cough with slight activity of chest and abdomen, 3 = Continuous cough with large amplitude activity of chest and abdomen, no limb activity, 4 = Continuous cough with large amplitude activity of chest and abdomen and limbs) During the procedure of general anesthesia induction, expected an average of 20 min.
Other heart rate Heart rate shown in the monitor During the procedure of general anesthesia induction, expected an average of 20 min.
Other pulse oxygen saturation (SpO2) SpO2 shown in the monitor During the procedure of general anesthesia induction, expected an average of 20 min.
Other level of recall At the 24-h postoperative follow-up visit, patients will be interviewed to assess their recall of pre-anesthesia events, administration of topical anesthesia, endoscopy and intubation. postoperative follow-up visit 24 hours after the operation, expected an average of 5 min.
Other satisfaction score At the 24-h postoperative follow-up visit, patients will be interviewed to assess their satisfaction about the procedure of awake intubation (1 = excellent, 2 = good, 3 = fair, 4 = poor). postoperative follow-up visit 24 hours after the operation, expected an average of 5 min.
Other adverse events At the 24-h postoperative follow-up visit, patients will be interviewed to assess the adverse events related to endotracheal intubation (postoperative hoarseness or sore throat) postoperative follow-up visit 24 hours after the operation, expected an average of 5 min.
Primary blood pressure systolic blood pressure (SBP), diastolic blood pressure (DBP), and mean blood pressure (MBP) shown in the monitor. During the procedure of general anesthesia induction, expected an average of 20 min
Secondary intubation condition score Assessment of the intubation condition according to the scale of the modified Erhan's intubation condition score which includes jaw relaxation, laryngoscopy, vocal cord position, and patient's response (coughing, limb movement) to intubation and inflation of the intubation tube cuff. During the procedure of general anesthesia induction, expected an average of 20 min
See also
  Status Clinical Trial Phase
Recruiting NCT03399019 - Bispectral Index(BIS) on Depth of Sedation With Dexmedetomidine, Propofol and Midazolam During Spinal Anesthesia N/A
Completed NCT03220880 - Intranasal Dexmedetomidine Sedation in Children for Non-painful Procedures
Recruiting NCT04820205 - Comparison of Oral Chloral Hydrate and Combination of Intranasal Dexmedetomidine and Ketamine for Procedural Sedation in Children N/A
Recruiting NCT04549623 - End-Tidal Carbon Dioxide Monitoring Device for Sedation During Endoscopic Ultrasonography N/A
Recruiting NCT04822064 - Comparison of Oral Chloral Hydrate and Combination of Intranasal Dexmedetomidine and Ketamine for Rescue After Failed Pediatric Procedural Sedation N/A
Completed NCT01527903 - A Comparison Between Propofol-Remifentanil and Midazolam-Remifentanil Sedation in the Intensive Care Unit Phase 4
Completed NCT01001533 - Assess the Ability of Electrical Cardiometry to Trend Hemodynamic Variables During Dexmedetomidine Sedation N/A
Completed NCT00747721 - Pharmacokinetics of Dexmedetomidine During Prolonged Infusion in ICU Phase 1
Completed NCT00158873 - Pharmaco-Economic Study Of Ultiva In Intensive Care Unit(ICU)Subjects Phase 4
Terminated NCT00205517 - Sedation and Psychopharmacology in Critical Care N/A
Recruiting NCT04096768 - The Use of Ketamine and Dexmedetomidine in Intensive Care Sedation Phase 3
Active, not recruiting NCT05082623 - The Effect of Music on Delirium, Pain, Need of Sedation, Anxiety and Vital Parameters N/A
Suspended NCT03285165 - Cerebral Vascular Effects of Dexmedetomidine Versus Propofol Sedation in Intubated Mechanically Ventilated ICU Patients Phase 2/Phase 3
Active, not recruiting NCT04788589 - Sedation and Ventilator Weaning Protocol in PICU N/A
Completed NCT03425474 - Study of Remimazolam Tosilate in Patients Undergoing Diagnostic Upper GI Endoscopy Phase 3
Recruiting NCT06061159 - The ED95 of Single Intravenous Bolus Remimazolam Besylate in Pediatric Patients During General Anesthesia Induction Phase 4
Completed NCT06449365 - Comparison of Intravenous V/S Nasal Atomizer Delivery of Midazolam for Conscious Sedation for No-scalpel Vasectomy Phase 4
Completed NCT02171910 - Doxapram as an Additive to Propofol Sedation in Sedation for ERCP Phase 4
Completed NCT02211118 - Sedation and Physiological Effects of Intranasal Dexmedetomidine in Severe COPD Phase 4
Completed NCT01694745 - EUROpean Pain Audit In Neonates N/A